Rising prevalence of genetic respiratory disorders, expanding healthcare infrastructure, and strong R&D investments fuel sustained market growth worldwide.Austin, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) ...
Shares of Beam Therapeutics BEAM were up 22.3% on Monday after the company outlined strategic priorities and some expected ...
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on ...
The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
The Graft Versus Host Disease (GvHD) market across the seven major markets (7MM) is anticipated to witness substantial ...
Quantitative CT in AATD linked airway wall thickening and bronchiectasis to lung function, while wall thickness best ...
Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research ...
Beam Therapeutics shares climbed after the company said it plans to file an application for its risto-cel treatment and had reached alignment with the Food and Drug Administration on potential ...
Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...
As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on ...
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results